Brief: Casi Pharmaceuticals Sees FY Revenue Up More Than 50%
16/02/2021 12:25
Feb 16 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER
AND
FULL-YEAR 2020 REVENUES AND PROVIDES BUSINESS UPDATES
* SEES FY REVENUE UP MORE THAN 50 PERCENT
* SEES Q4 2020 REVENUE ABOUT $4.8 MILLION
* SEES FY 2020 REVENUE ABOUT $15 MILLION
Source text for Eikon: ID:nPn7Rwf4Ca
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary